Agios CSO to depart amid layoffs as biotech looks for new drugs to license or acquire
A year and a half after ending work in oncology and three months after securing the first nod for its new “anchor product,” Agios is once again shaking things up.
As many as 50 exploratory research employees will be let go and chief scientific officer Bruce Car will depart the company at the end of July, the biotech said after the closing bell Monday. That represents nearly 13% of the workforce that Agios employed at the end of 2021, with 390 full-time workers as of December 31.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.